Life Sciences team advises Crescendo Biologics on $790 million collaboration with Takeda Pharmaceutical Company

31 October 2016

Crescendo Biologics turned to Gowling WLG's Life Sciences team, led by partner Patrick Duxbury, for assistance on its collaboration with Takeda Pharmaceutical Company with the aim of discovering, developing and commercialising Humabody®-based therapeutics aimed at cancer indications with a high unmet medical need. 

Crescendo will use its patented transgenic platform and protein engineering expertise to develop Humabody® candidates against targets nominated by Takeda.

Under the term of the collaboration, Crescendo is entitled to receive up to $36 million via a series of milestones, funding, investment and upfront payment, while Takeda has the right to develop and commercialise selected Humabody®-based therapeutics arising from the partnership, triggering further payments of up $754 million.

The deal completed in October 2016. 


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Life Sciences